Market for this liver drug could rival hepatitis C By: CNBC.com News July 15, 2014 at 08:06 AM EDT NASH, or nonalcoholic steatohepatitis, is becoming more widespread, and the market for treatments for the liver disorder may rival those for hepatitis C. Read More >> Related Stocks: Gilead Sciences Intercept Pharmaceuticals Vertex Pharmaceuticals